{"groups":[{"description":"50 mg BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.","id":"FG000","title":"BION-1301 50 mg Q2W"},{"description":"150 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"FG001","title":"BION-1301 150 mg Q2W"},{"description":"450 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"FG002","title":"BION-1301 450 mg Q2W"},{"description":"1350 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"FG003","title":"BION-1301 1350 mg Q2W"},{"description":"2700 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"FG004","title":"BION-1301 2700 mg Q2W"},{"description":"1350 mg BION-1301 will be administered as an IV infusion once per week for up to 8 weeks, followed by dosing once every 2 weeks.","id":"FG005","title":"BION-1301 1350 mg QW*8W->Q2W"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Subject enrollment was stopped prematurely due to the sponsor's decision to terminate the study. Therefore, the study did not proceed to the Phase 2 portion of the study protocol. All reporting groups are for Phase 1 only."}